Compare STRW & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRW | CRBP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 190.3M |
| IPO Year | 2019 | 2014 |
| Metric | STRW | CRBP |
|---|---|---|
| Price | $12.28 | $3.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $15.64 | ★ $34.89 |
| AVG Volume (30 Days) | 38.5K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ 5.26 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $154,999,000.00 | $4,822,272.00 |
| Revenue This Year | $4.07 | N/A |
| Revenue Next Year | $5.80 | $131.00 |
| P/E Ratio | $39.21 | ★ N/A |
| Revenue Growth | 32.41 | ★ 97.62 |
| 52 Week Low | $11.53 | $3.57 |
| 52 Week High | $14.75 | $12.88 |
| Indicator | STRW | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.92 | 21.37 |
| Support Level | $12.14 | N/A |
| Resistance Level | $13.35 | $8.13 |
| Average True Range (ATR) | 0.53 | 0.33 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 29.18 | 14.57 |
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.